Publications by authors named "Juan Francisco Rodriguez Moreno"

Article Synopsis
  • Precision medicine is changing how we treat cancer, but many patients still lack access to the necessary genetic testing and treatments.
  • A study in Spain examined how providing free RNA sequencing tests impacted the treatment of solid cancer patients who had already failed standard therapies, analyzing samples from 395 patients.
  • The results showed actionable genetic alterations in 14.4% of patients, leading to limited use of targeted therapies, highlighting a need for better access to comprehensive molecular testing and personalized treatments.
View Article and Find Full Text PDF

Background: Granulosa cell ovarian tumors (GCT) are orphan disease with limited treatments. Hormone therapy is a potential treatment, due to the overexpression of hormone receptors in most tumors. This study explores the activity of the antiandrogen, enzalutamide, in metastatic cases.

View Article and Find Full Text PDF

Background And Purpose: Despite that incorporating antiangiogenic in combination with immune-checkpoint inhibitors as the standard first-line treatment for advanced clear cell renal cell cancer (ccRCC) yields promising outcomes, these regimens often lead to significant toxicity. However, a subgroup of patients has shown responsiveness to VEGFR tyrosine-kinase inhibitors (TKIs) in monotherapy, leading to the question of whether employing combination therapies can significantly enhance overall survival in all patients over monotherapy. Thus, we aim to identify gene expression signatures that can predict TKI response within subpopulations that might benefit from single-agent therapies, to minimize unnecessary exposure to combination therapies and their associated toxicities, as well as to discover new potential therapeutic targets to improve ccRCC treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer patients with COVID-19 had to stop their treatments and went to the hospital more often than those without COVID-19.
  • The study looked at 85 kidney cancer patients, comparing those who had COVID-19 while on different treatments.
  • Even though COVID-19 caused treatment issues, it didn't seem to hurt the cancer outcomes for the patients.
View Article and Find Full Text PDF

Background: Managing the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.

Methods: We designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19.

View Article and Find Full Text PDF

Background: Granulosa cell ovarian tumor (GCT) is characterized by a pathognomonic mutation in the FOXL2 gene (402 C > G) that leads to an overactivation of steroidogenesis. CYP17 is a key enzyme in such process and can be inhibited by ketoconazole.

Methods: We designed a phase II clinical trial to assess the efficacy of ketoconazole in advanced GCT and conducted several in vitro studies to support the clinical findings.

View Article and Find Full Text PDF

Background: The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ("GRAVID").

Methods: The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are trying to find specific types of prostate cancer that can be treated with special medicines, and they discovered something unusual called a BRAF fusion in some patients.
  • They studied 41 patients with advanced prostate cancer to look for rare changes in their genes, which could help understand and treat these cancers better.
  • One patient had a unique gene change and responded really well to a medicine called trametinib, showing that certain prostate cancers might need special treatments based on their unique gene setups.
View Article and Find Full Text PDF

Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable target, key to the pathogenesis of some urothelial cancers (UCs). Though FGFR GAs are common in noninvasive UC, little is known about their role in the metastatic(m) setting and response to therapy. This study aimed to assess the impact of FGFR alterations on sensitivity to systemic treatments and survival and to validate Bajorin's and Bellmunt's prognostic scores in mUC patients according to their FGFR status.

View Article and Find Full Text PDF
Article Synopsis
  • The recombinant zoster vaccine (RZV) showed over 90% effectiveness against herpes zoster in adults over 50 and was tested on cancer patients receiving chemotherapy to evaluate its safety and immune response.
  • In a randomized study, participants were given either the RZV or a placebo, with immune responses measured at various intervals post-vaccination.
  • Results indicated that RZV recipients had stronger immune responses compared to those receiving a placebo, with no serious safety issues noted over a year of follow-up.
View Article and Find Full Text PDF

Testicular germ cell tumors (TGCTs) are a clinically and pathologically heterogeneous disease, and little is known of its genetic basis. Only low susceptibility risk loci have been identified for both sporadic and familial cases. Therefore, we tried to identify new susceptibility genes responsible for familial testicular cancer that may contribute to increasing our knowledge about the genetic basis of the disease.

View Article and Find Full Text PDF

mTOR pathway inhibitors are important drugs for the treatment of advanced renal cell carcinoma (RCC). However, no valid predictive markers have been identified to guide treatment selection and identify patients who are sensitive to these drugs. Mutations activating the mTOR pathway have been suggested to predict response; however, their predictive value is still unclear.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explored the relationship between circulating endothelial cells (CECs) in the blood and long-term benefits from first-line treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC) to find predictors of treatment response.
  • - Conducted across 13 institutions, 75 adult patients were monitored over 15 months, revealing that higher baseline CEC levels correlated with significantly longer progression-free survival (22.2 months vs. 12.2 months) compared to lower levels.
  • - The findings indicate that elevated CEC levels under antiangiogenic treatment may serve as a useful indicator of clinical benefit, although no significant changes in CEC levels were observed at tumor progression.
View Article and Find Full Text PDF

Uterine cervical cancer is the second most common gynecological malignancy. It is estimated that over 35% of tumors are diagnosed at locally advanced disease, stage IB2-IIB with an estimated 5-year overall survival of 60%. During the last decades, the initial treatment for these women has been debated and largely varies through different countries.

View Article and Find Full Text PDF

Molecular knowledge has deeply affected the treatment and outcome of kidney cancer in recent years, and several therapeutic options have become available. However, there are no validated biomarkers to select the best drug for each patient. Already published studies and ongoing investigations could change this scenario in the near future.

View Article and Find Full Text PDF

Borderline ovarian tumours generally affect women of reproductive age. The positive prognosis is related to the fact that over 80% of cases are diagnosed at an early stage of the disease. Although radical surgery is the standard of care for this disease, fertility-sparing surgery can be performed in selected cases.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted therapies, especially when combined with chemotherapy, have shown to enhance response rates and improve survival in various solid tumors.
  • Trastuzumab is a key monoclonal antibody that has beneficial effects on breast cancer cells but also poses risks to heart health due to shared signaling pathways.
  • Current research is focused on developing better monitoring and risk management strategies to ensure more patients can safely receive trastuzumab, rather than limiting its use.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: